@article{66fed63907a84bd1a1101eef86386a9a,
title = "Frontal theta cordance predicts 6-month antidepressant response to subcallosal cingulate deep brain stimulation for treatment-resistant depression: A pilot study",
abstract = "Deep brain stimulation (DBS) of subcallosal cingulate white matter (SCC) may be an effective approach for treatment-resistant depression (TRD) that otherwise fails to respond to more conventional therapies, but DBS is invasive, costly, and has potential for adverse effects. Therefore, it is important to identify potential biomarkers for predicting antidepressant response before intervention. Resting-state EEG was recorded from 12 TRD patients at pre-treatment baseline, after 4 weeks SCC DBS, and after 24 weeks SCC DBS. Lower frontal theta cordance (FTC) at baseline (and higher FTC after 4 weeks) predicted lower depression severity scores after 24 weeks. Greater FTC increases (baseline-4 weeks) predicted greater decreases in depression severity scores subsequently (4-24 weeks) and over the course of the study (baseline-24 weeks). Predictive relationships were topographically specific to theta cordance for frontal electrodes. Thus, results from this pilot study suggest that baseline FTC and changes early in treatment each have utility as biomarkers for predicting 6-month clinical response to SCC DBS for TRD.",
keywords = "biomarker, deep brain stimulation, depression, EEG, theta cordance",
author = "Broadway, {James M.} and Holtzheimer, {Paul E.} and Hilimire, {Matthew R.} and Parks, {Nathan A.} and Devylder, {Jordan E.} and Mayberg, {Helen S.} and Corballis, {Paul M.}",
note = "Funding Information: Mr Broadway, Mr Hilimire, Dr Parks, Mr DeVylder, and Dr Corballis declare no conflict of interest. Dr Holtzheimer has received grant funding from the Greenwall Foundation, NARSAD, National Institutes of Health Loan Repayment Program, NIMH, and Northstar; he has received consulting fees from AvaCat Consulting, St Jude Medical and Oppenheimer. Dr Mayberg has a consulting agreement with St Jude Medical, which has licensed her intellectual property to develop SCC DBS for the treatment of severe depression (US 2005/0033379A1). The terms of these arrangements have been reviewed and approved by Emory University in accordance with their conflict of interest policies. Dr Mayberg has current grant funding from the Dana Foundation, NARSAD, National Institute of Mental Health (NIMH), Stanley Medical Research Institute, and Woodruff Foundation. Funding Information: This study was funded by grants from the Dana Foundation (HSM), Stanley Medical Research Institute (HSM), Woodruff Foundation (HSM), Emory Healthcare (HSM), and K23 MH077869 (PEH). Devices were donated by Advanced Neuromodulation Systems/St Jude Medical Neuromodula-tion. We thank Andrea Barrocas, Megan Filkowski, and Margaret Craighead for assistance with patient coordination. In addition, the authors would like to thank Alex Alverson for assistance with data collection.",
year = "2012",
month = jun,
doi = "10.1038/npp.2012.23",
language = "English (US)",
volume = "37",
pages = "1764--1772",
journal = "Neuropsychopharmacology",
issn = "0893-133X",
publisher = "Nature Publishing Group",
number = "7",
}